sever
envelop
rna
virus
arenaviru
bunyaviru
filoviru
flaviviru
famili
associ
syndrom
known
viral
hemorrhag
fever
vhf
vhf
character
fever
vascular
leakag
coagul
defect
multi
organ
system
failur
vhf
current
view
diseas
precipit
viral
suppress
innat
immun
promot
system
viru
replic
excess
proinflammatori
cytokin
respons
trigger
manifest
sever
diseas
howev
mechan
immun
dysregul
contribut
diseas
remain
poorli
understood
infect
nonhuman
primat
close
recapitul
human
vhf
notabl
ebola
yellow
fever
therebi
provid
excel
model
better
defin
immunolog
basi
syndrom
review
current
state
knowledg
suggest
futur
direct
better
defin
immunolog
mechan
underli
vhf
among
wellknown
caus
vhf
filovirus
ebola
viru
ebov
marburg
viru
marv
arenaviru
lassa
viru
flavivirus
yellow
fever
yfv
dengu
denv
viru
divers
viru
famili
differ
replic
strategi
caus
similar
clinic
syndrom
incomplet
understood
sever
featur
typifi
infect
virus
effect
suppress
innat
antivir
defens
replic
system
high
titer
monocyt
macrophag
dendrit
cell
target
infect
system
cytokin
storm
occur
vascular
leakag
hemorrhag
may
seen
nevertheless
specif
detail
immunolog
underpin
vhf
lack
unifi
view
viru
innat
immun
respons
adapt
immun
respons
interact
set
vhf
also
absent
argu
avail
wellestablish
nonhuman
primat
model
ebov
yfv
diseas
provid
necessari
tool
defin
immunolog
featur
common
vhf
lead
greater
understand
syndrom
suggest
novel
therapeut
approach
ebolavirus
marburgvirus
envelop
virus
nonseg
negativesens
singlestrand
rna
genom
belong
famili
filovirida
speci
ebolaviru
zair
ebolaviru
ebov
sudan
ebolaviru
sudv
bundibugyo
ebolaviru
bdbv
tai
forrest
ebolaviru
tafv
reston
ebolaviru
restv
singl
speci
marburgviru
marburg
marburgviru
marv
ebov
sudv
bdbv
marv
associ
outbreak
sever
diseas
high
mortal
human
detail
descript
filoviru
diseas
come
studi
ebov
form
main
basi
discuss
filoviru
hemorrhag
fever
filoviru
genom
possess
gene
encod
nucleoprotein
np
viral
protein
kda
glycoprotein
gp
mediat
viral
attach
entri
larg
protein
l
enzymat
compon
viral
rnadepend
rna
polymeras
ebov
replic
cycl
take
place
cytoplasm
viru
releas
occur
bud
plasma
membran
process
direct
matrix
protein
enhanc
viral
protein
includ
gp
infect
occur
due
direct
contact
infecti
materi
bodili
fluid
contain
infecti
viru
airborn
transmiss
thought
signific
rout
human
infect
aerosol
viru
caus
rapidli
lethal
diseas
experimentallyinfect
nonhuman
primat
review
follow
exposur
incub
period
day
follow
abrupt
nonspecif
viral
syndrom
character
fever
chill
myalgia
infect
progress
prostrat
nausea
vomit
abdomin
pain
diarrhea
appear
final
stage
diseas
character
coagulopathi
vascular
leakag
result
hemorrhag
shock
review
mani
detail
ebov
pathogenesi
deriv
nonhuman
primat
studi
close
parallel
sever
human
infect
consid
goldstandard
model
ebov
diseas
evd
hallmark
evd
high
level
system
viru
replic
cytokin
product
liver
damag
coagulopathi
lymphopenia
although
filovirus
product
infect
varieti
cell
type
dendrit
cell
dc
macrophag
monocyt
appear
preferenti
target
may
due
viral
gp
interact
lectin
dendriticcellspecif
nonintegrin
dcsign
surfac
cell
phosphatidylserin
surfac
viru
particl
interact
either
directli
intermedi
molecul
tam
integrin
immun
cell
support
product
viral
infect
capabl
traffick
vivo
infect
like
facilit
dissemin
viru
lymph
node
system
dissemin
ebov
hepatocyt
adren
cortic
cell
endotheli
cell
like
contribut
coagulopathi
result
hemorrhag
shock
virusinduc
liver
damag
reduc
product
coagul
factor
infect
adren
gland
reduc
product
hormon
regul
blood
pressur
addit
infect
monocyt
macrophag
produc
proinflammatori
mediat
reactiv
oxygen
speci
nitric
oxid
tissu
factor
tf
promot
endotheli
leakag
hypovolemia
cellular
sensor
signal
pathway
ebov
infect
promot
product
cytokin
chemokin
monocyt
incomplet
defin
vitro
studi
demonstr
extens
ebov
replic
requir
elicit
cytokin
product
like
sustain
cytokin
respons
contrast
monocytesmacrophag
ebov
infect
dc
character
inhibit
cytokin
product
downregul
costimulatori
molecul
reduc
abil
activ
cell
protein
target
multipl
innat
immun
signal
pathway
suppress
product
antivir
effect
xray
crystal
structur
demonstr
ebov
marv
bind
phosphodiest
backbon
dsrna
ebov
also
cap
end
dsrna
manner
could
mask
ebov
also
interact
cellular
protein
pact
prevent
pactmedi
activ
rigi
mutat
disrupt
interact
dsrna
pact
abrog
inhibit
ifn
respons
furthermor
mutat
impair
viru
replic
compet
cell
attenu
viru
vivo
demonstr
critic
role
innat
immun
suppress
pathogenesi
addit
ebov
marv
block
jakstat
signal
pathway
trigger
ifn
ad
cell
therebi
disrupt
antivir
effect
cytokin
ebov
block
nuclear
accumul
tyrosin
phosphoryl
bind
subfamili
karyopherin
alpha
kpna
protein
wherea
marv
block
signal
tyrosin
kinas
prevent
tyrosin
phosphoryl
event
typic
occur
ifn
addit
cell
impact
dc
suppress
adapt
immun
vivo
remain
determin
virusspecif
cell
respons
develop
ebovinfect
mice
peopl
surviv
infect
moreov
lymphopenia
anoth
common
featur
ebov
infect
loss
cell
cell
nk
cell
mous
nonhuman
primat
model
well
human
patient
cell
loss
occur
primarili
via
apoptosi
although
basi
phenomenon
yet
clear
believ
mediat
proinflammatori
cytokin
solubl
fa
ligand
produc
monocytesmacrophag
yfv
endem
central
africa
south
america
result
approxim
case
death
annual
yfv
arboviru
spread
via
mosquito
belong
genera
haemagogu
aed
yfv
maintain
two
life
cycl
urban
cycl
yfv
transmit
human
via
aed
aegypti
jungl
cycl
yfv
transmiss
occur
nonhuman
primat
via
hemagogu
mosquito
south
america
aed
africanu
africa
human
infect
mosquito
previous
fed
infect
monkey
like
member
flavivirida
famili
yfv
singl
posit
strand
rna
viru
genom
compos
noncod
region
singl
openread
frame
orf
noncod
region
orf
encod
structur
protein
capsid
c
membran
prm
envelop
e
nonstructur
protein
viru
protein
process
translat
entir
polyprotein
within
rough
endoplasm
reticulum
er
main
structur
protein
envelop
anchor
lipid
bilay
viral
envelop
play
import
role
viral
entri
nonstructur
protein
mainli
involv
rna
replic
posttransl
cleavag
viru
polyprotein
yfv
cell
entri
mediat
surfac
e
protein
intern
via
clathrindepend
endocytosi
lowph
environ
endosom
induc
uncoat
viru
viral
rna
genom
releas
cytoplasm
replic
occur
posit
sens
rna
translat
either
synthes
complementari
neg
rna
strand
serv
templat
progeni
posit
strand
encod
structur
protein
virion
assembl
viral
enzym
requir
replic
posttransl
process
yfv
elicit
two
pattern
injuri
viscerotrop
neurotrop
yfv
primarili
caus
viscerotrop
diseas
human
nonhuman
primat
lesion
observ
multipl
organ
liver
spleen
heart
kidney
golden
hamster
immunodefici
mice
mice
develop
studi
yfv
infect
howev
limit
model
hamster
model
requir
hamsteradapt
strain
yfv
infect
immunodefici
mice
vaccin
strain
result
enceph
viscerotrop
diseas
observ
nonhuman
primat
human
hamper
studi
host
immun
respons
yfv
contrast
nonhuman
primat
robust
model
studi
yfv
sinc
natur
reservoir
jungl
cycl
transmiss
clinic
manifest
follow
yfv
challeng
rhesu
macaqu
mimic
human
viscerotrop
diseas
approxim
yfv
first
introduc
epidermi
via
saliva
bloodfeed
mosquito
previou
studi
suggest
dendrit
cell
resid
epidermi
import
earli
target
flaviviru
replic
viru
spread
via
infect
dc
lymphat
channel
drain
lymph
node
subsequ
bloodstream
eventu
dissemin
liver
spleen
addit
lymph
node
heart
kidney
yellow
fever
present
three
distinct
stage
infect
remiss
intox
infect
last
day
initi
mosquito
bite
character
onset
fever
headach
malais
photophobia
backach
myalgia
irrit
nausea
viremia
peak
day
onset
symptom
remiss
last
hour
fever
symptom
subsid
patient
recov
approxim
patient
becom
sever
ill
enter
period
intox
patient
develop
jaundic
oliguria
anuria
cardiovascular
instabl
hemorrhag
fever
multiorgan
dysfunct
casefat
rate
patient
develop
viscer
diseas
jaundic
rang
hepat
dysfunct
hallmark
yfv
character
eosinophil
degener
hepatocyt
known
councilman
bodi
kupffer
cell
fa
mediat
midzon
hepatocellular
apoptosi
absenc
inflamm
steatosi
predomin
apoptot
versu
necrot
liver
injuri
may
explain
minim
inflamm
infiltr
renal
patholog
character
eosinophil
degener
fatti
chang
renal
tubular
epithelium
without
inflamm
similar
ebola
hemorrhag
fever
cytokin
dysregul
thought
mediat
endotheli
damag
dissemin
intravascular
coagul
circulatori
shock
observ
termin
stage
yfv
thrombocytopenia
prolong
clot
prothrombin
time
observ
human
patient
nonhuman
primat
due
diminish
liver
product
fibrinogen
clot
factor
yellow
fever
viru
employ
strategi
evad
host
innat
immun
inhibit
type
interferon
respons
whose
function
conserv
among
flavivirus
block
activ
interferon
stimul
gene
express
vero
cell
addit
recent
studi
character
gene
express
within
peripher
blood
mononuclear
cell
rhesu
macaqu
day
post
yfv
infect
report
downregul
gene
associ
innat
immun
includ
interferon
gamma
receptor
marker
dc
matur
hypothes
induc
dc
stimul
cell
prolifer
import
evas
innat
immun
pathogenesi
yfv
highlight
reduc
mortal
rhesu
macaqu
treat
polyriboinosinicpolyribocytidyl
acid
polyllysin
carboxymethylcellulos
induc
similarli
administr
reduc
viremia
hepat
sever
squirrel
monkey
prolong
surviv
time
rhesu
macaqu
similar
ebov
yfv
infect
also
result
profound
lymphopenia
deplet
lymphocyt
germin
center
spleen
lymph
node
tonsil
peyer
patch
observ
rhesu
macaqu
infect
yfv
strain
circul
lymphocyt
declin
anim
requir
euthanasia
compar
decreas
anim
surviv
challeng
signific
neg
correl
viral
load
extent
lymphocyt
loss
loss
lymphocyt
like
due
cytokin
storm
accompani
yfv
infect
level
proinflammatori
modul
antiinflammatori
cytokin
significantli
higher
patient
fatal
yellow
fever
compar
patient
surviv
similarli
level
ifni
elev
rhesu
macaqu
infect
yellow
fever
strain
host
respons
infect
play
promin
role
evd
yfv
viscerotrop
diseas
direct
demonstr
specif
interact
viru
host
immun
respons
contribut
vhf
vivo
larg
lack
avail
welldevelop
anim
model
provid
opportun
address
gap
knowledg
use
inform
develop
new
therapeut
approach
although
know
great
deal
filovir
regul
viral
replic
suppress
ifn
respons
vitro
contribut
function
pathogenesi
vhf
vivo
remain
poorli
defin
recombin
ebov
point
mutat
attenu
rodent
model
howev
model
fulli
recapitul
human
vhf
therefor
address
role
vhf
primat
must
infect
mutant
virus
role
innat
immun
evas
viral
replic
easili
separ
earli
time
point
examin
uncov
chang
dc
monocyt
activ
drain
lymph
node
mutant
ebov
found
modestli
impact
dc
matur
phenotyp
vitro
howev
mutat
may
complet
inactiv
ifnantagonist
function
recent
structur
function
studi
defin
new
amino
acid
residu
ebov
critic
suppress
ifn
signal
investig
vivo
final
addit
studi
requir
defin
contribut
marv
identifi
addit
yfv
protein
contribut
suppress
innat
immun
impact
pathogenesi
vivo
excess
proinflammatori
cytokin
product
thought
major
factor
pathogenesi
vhf
although
respons
infect
monocyt
macrophag
vitro
suggest
cell
sourc
inflammatori
cytokin
cell
type
relev
inflammatori
respons
vivo
signal
pathway
contribut
respons
role
viru
infect
trigger
respons
remain
defin
deplet
specif
immun
cell
subset
togeth
transcriptom
phenotyp
analysi
monocyt
isol
infect
human
nonhuman
primat
acut
infect
would
help
address
question
vitro
studi
attribut
ebovinduc
endotheli
leakag
cytokin
tf
solubl
gp
vivo
studi
suggest
mechan
destruct
endothelium
viru
replic
although
complic
address
nhp
use
cytokineneutr
antibodi
specif
inhibitor
ebov
yfvinfect
anim
could
clarifi
diseas
mechan
suggest
therapeut
approach
contribut
liver
damag
damag
adren
gland
coagulopathi
low
blood
pressur
also
need
examin
statu
adapt
immun
respons
suppress
dc
matur
vitro
suggest
ebov
may
impair
develop
cell
respons
fatal
infect
associ
absenc
specif
antibodi
respons
apoptot
loss
lymphocyt
find
suggest
defect
adapt
immun
cours
infect
howev
survivor
develop
specif
cell
respons
therefor
import
character
statu
adapt
immun
respons
vivo
import
question
answer
includ
mechan
lymphocyt
apoptosi
dysregul
lymphocyt
activ
prolifer
use
care
examin
lymphocyt
transcriptom
phenotyp
ex
vivo
use
clinic
sampl
nonhuman
primat
model
avail
welldevelop
anim
model
ebov
yfv
afford
opportun
address
gap
knowledg
use
inform
develop
new
therapeut
approach
possibl
take
advantag
differ
virus
within
famili
differ
degre
virul
exampl
wherea
intramuscular
inject
zair
ebov
nearli
percent
lethal
macaqu
compar
inject
bundibugyo
ebov
percent
lethal
examin
host
respons
survivor
versu
lethal
infect
either
viru
could
highlight
featur
determin
outcom
infect
moreov
similar
pathogen
mechan
employ
ebov
yfv
suggest
yfv
may
serv
model
ebola
hemorrhag
fever
one
major
advantag
yfv
abil
studi
biosafeti
level
condit
contrast
studi
ebov
filovirus
requir
biosafeti
level
contain
facil
avail
hand
research
worldwid
infect
ebov
yfv
occur
viru
breach
epithelialmucos
barrier
may
occur
follow
exposur
ebov
break
skin
mucos
epithelium
yfv
occur
via
mosquito
bite
macrophag
dendrit
cell
import
earli
target
infect
cell
support
product
replic
also
traffic
local
lymph
node
tissu
organ
therebi
promot
system
dissemin
infect
damag
differ
organ
promot
indic
patholog
process
infect
macrophag
also
result
prolif
product
cytokin
commonli
refer
cytokin
storm
promot
vascular
leakag
hypotens
activ
coagul
pathway
ultim
lead
dissemin
intravascular
coagul
also
cytokin
like
contribut
apoptosi
lymphocyt
infect
dendrit
cell
lead
dysregul
phenotyp
interferon
ifn
respons
suppress
matur
dendrit
cell
impair
like
inhibit
activ
cell
prevent
control
infect
